Cybin to Participate in the 2025 Psychedelic Science Conference
Article content
Article content
– Cybin CEO Doug Drysdale to participate in a panel discussion titled 'The Home Stretch: Pivotal Trials and Preparing for Launch' on June 19, 2025 –
Article content
Article content
TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the Psychedelic Science 2025 Conference taking place June 16-20, 2025 in Denver, Colorado. The details are as follows:
Article content
Panel Title:
Article content
Date and Time:
Article content
Thursday, June 19, 2025 at 9:30 a.m. MDT (11:30 a.m. EDT)
Article content
'This annual gathering of global experts is a unique opportunity to share perspectives and engage with others on the forefront of achieving the potential of psychedelic therapeutics,' said Doug Drysdale, Chief Executive Officer of Cybin. 'Cybin is fully committed to advancing our ongoing clinical work and delivering innovative alternatives to the current standard of care to address the large unmet medical need in treating mental health disorders. Recognition of this potential within medical circles has never been greater, and I am pleased to be part of the panel that is focused on these crucial next steps along the regulatory pathway.'
Article content
About Cybin
Article content
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
Article content
Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Article content
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Government Mandate Sends eVTOL Stocks Flying
For years, the promise of electric air taxis existed primarily in prototypes and investor presentations. In 2025, that reality has changed, and the electric vertical takeoff and landing (eVTOL) industry is now poised to accelerate dramatically. On June 6, 2025, the White House issued a sweeping Executive Order designed to expedite advanced aviation in the United States. This directive gave the fledgling Urban Air Mobility (UAM) sector a powerful federal green light. The policy sent immediate ripples through the market, validating the industry at the highest level of government. The reaction was swift. On the next trading day, June 9, shares of Joby Aviation (NYSE: JOBY) were up 13.79% on a spike in trading volume. Its primary rival, Archer Aviation (NYSE: ACHR), saw its stock climb 10.99%, also on higher-than-normal trading volume. This clear market enthusiasm signals the belief among eVTOL industry observers that a new, more certain investment era has begun for this transformative industry. Why the Executive Order Is a Game-Changer The market's reaction is rooted in specific policies that directly address the sector's most significant risks. For investors, these changes create a more transparent and predictable path to commercial operations. First, the order creates the "eVTOL Integration Pilot Program" (ePIPP). This is the most significant development. The program directs the Federal Aviation Administration (FAA) to select at least five U.S.-based eVTOL projects by December 3, 2025. These projects, covering cargo, medical, and passenger transport, can begin limited operations. This creates a formal, government-sanctioned pathway for companies to prove their business model and gather crucial operational data years ahead of schedule. Second, the order establishes a clearer regulatory runway. A significant risk for eVTOL investors has been the uncertain and potentially lengthy FAA certification timeline. This new government mandate imposes firm deadlines on the FAA. This federal tailwind helps reduce investor concern over indefinite delays that can stall progress in capital-intensive industries. Finally, the order gives a Made in America advantage. The policy explicitly directs federal agencies to prioritize U.S.-manufactured aircraft. This helps secure the valuable domestic market for companies like Joby and Archer against foreign competitors, supporting a more robust national supply chain. The Pioneer vs. the Scaler: Choosing Your eVTOL Investment The Executive Order lifted both leading stocks, but the companies offer different approaches to capitalizing on this new opportunity. For investors, the choice comes down to which business model seems best positioned to win in this accelerated environment. Joby Aviation: A Bet on Technical Leadership [content-module:Forecast|NYSE:JOBY] Joby's strategy is built on deep, vertical integration. The company maintains complete control over its aircraft's performance and intellectual property by designing and building its technology stack in-house. This makes Joby an investment in long-term technical superiority. Evidence of this strategy's effectiveness can be seen in its operational progress. Joby is the frontrunner in the FAA certification process and has accumulated over 40,000 miles in flight testing, including complex piloted flights that demonstrate the maturity of its aircraft. The company is well-capitalized, with a cash position exceeding $1 billion after its latest infusion from Toyota (NYSE: TM). This manufacturing partnership with an industrial giant like Toyota is critical, as it underpins Joby's ability to scale its advanced, proprietary technology. Archer Aviation: A Bet on Rapid Scalability [content-module:Forecast|NYSE:ACHR] Archer's strategy prioritizes capital efficiency and speed to market through powerful partnerships. By teaming up with industrial leaders, Archer aims to de-risk the challenges of mass production. This makes Archer an investment in a faster, more capital-light path to commercial scale. This approach is validated by its exclusive contract manufacturing agreement with automotive giant Stellantis (NYSE: STLA), a partnership aimed at producing up to 650 aircraft per year. Archer's commercial viability is further supported by a massive conditional order book, highlighted by a $1.0 - $1.5 billion deal with United Airlines. The company has also proven its ability to execute by delivering its first Midnight aircraft to the U.S. Air Force, meeting a key government milestone. Final Approach: Opportunity in the Updraft The June 6 Executive Order is undeniably one of the most significant catalysts in the eVTOL sector's history. It validates the industry at a national level and significantly accelerates the timeline for demonstrating commercial potential. While the new ePIPP program creates a vital near-term pathway, investors must remember that it does not replace the need for full FAA Type Certification. This final regulatory approval remains the ultimate gatekeeper for widespread, unrestricted passenger service. The primary question for investors is no longer if a path to early operations exists, but which company is best positioned to leverage this pilot program to its advantage while continuing to advance toward final certification and scaled manufacturing. Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now...
Globe and Mail
3 hours ago
- Globe and Mail
Prediction: Palantir Stock Will Plummet in the Second Half of 2025. The Reason Why Is Obvious.
Data mining specialist Palantir Technologies (NASDAQ: PLTR) picked up right where it left off in 2024. Last year, Palantir stock was the top performer in the S&P 500 index, as well as the third-best stock in the Nasdaq-100. So far in 2025, things haven't changed much for the artificial intelligence (AI) software player -- as shares have rocketed by an eye-popping 74% as of this writing (June 10). While the momentum doesn't appear to be slowing down at all for Palantir, my prediction is that the stock will plummet during the second half of the year. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Let's explore some of the trends fueling Palantir stock right now, as well as some interesting breadcrumbs that could support my idea that shares are headed for a sell-off. Should you dump your Palantir position right now? Read on to find out. Palantir's valuation is sky high, and... There is a lot that can be gathered from the chart below. The obvious takeaway is that Palantir's price-to-sales (P/S) multiple of 105 is significantly higher than any of the software growth stocks in this peer set. However, the bigger idea from the analysis below is that Palantir's valuation continues to expand. PLTR PS Ratio data by YCharts These dynamics imply that investors are buying Palantir stock in droves. The deeper question I've been asking is: Who are the investors that keep chasing Palantir's momentum? Based on some recent clues, I think I might have an answer. ...smart investors are taking profits Ark Invest CEO Cathie Wood is one of the original Palantir bulls on Wall Street. Shortly following the company's IPO in late 2020, Wood appeared on financial news programs on a regular basis -- constantly talking about her excitement around Palantir and the company's ability to disrupt legacy software providers. While this was a great source of indirect PR for Palantir, Wood shocked the investment world when she dumped her stake sometime in 2022. Following these moves, Wood started accumulating a position in Palantir stock once again in 2023. Per the graph in the prior section, Ark Invest's position in Palantir is sitting on a healthy profit considering shares now hover around all-time highs. Wood has taken note of these trends, and the famous tech investor is once again reducing her exposure to Palantir. Wood isn't the only notable personality on Wall Street that's choosing to take profits in Palantir, though. Billionaire investor Stanley Druckenmiller of the Duquesne Family Office completely exited Palantir during the first quarter, per the fund's most recent 13F filing. Similar to Wood, Druckenmiller has also been in and out of Palantir stock in recent years. I view the decision to reduce exposure to Palantir stock right now as a prudent one. While the selling from Wood and Druckenmiller does not necessarily imply a bearish view of Palantir at all, I think trimming exposure and taking profits in a stock that seems overbought makes sense. My prediction is that more institutions will follow in the second half of 2025 Palantir's valuation is historically high, even compared to what investors witnessed during the peak bubble days of the dot-com boom. I think a rising number of institutions will come to the opinion that Palantir's current valuation trajectory is not sustainable given how far the stock has already run. PLTR Shares Increased by Institutional Investors data by YCharts The graph above illustrates the number of shares of Palantir stock that have increased and decreased by institutional investors over the last year. As the trends indicate, there was pronounced institutional buying of Palantir stock during the last few months of 2024. At the same time, the orange line -- which indicates institutional selling -- also steadily climbed during late 2024 and ultimately converged with the purple line (buyers) at the start of 2025. Right now, shares bought by institutions remains higher than shares sold, which implies large investors are net buyers of Palantir stock for the time being. Throughout this year, both buying and selling activity has decelerated -- as indicated by the relative flattening of both lines. These trends suggest that while institutions remain cautiously optimistic about Palantir, there could be further selling on the horizon as the narrowing gap between buyers and sellers becomes more obvious. As such, I think the current momentum fueling Palantir stock could tempt more institutions to dump their shares -- leading to a plummeting share price and much-needed valuation normalization. Ultimately, I don't think dumping your position in Palantir is entirely necessary. As a long-term investor, it's important to hold on to your highest-conviction winners. However, I do think taking some gains off the table could be a smart decision right now. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
8 hours ago
- Globe and Mail
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
